Aligos Therapeutics, Inc. (ALGS) |
|
1.17 -0.03 (-2.5%)
|
03-22 15:03 |
|
Open: |
1.19 |
Pre. Close: |
1.2 |
|
High:
|
1.26 |
Low:
|
1.17 |
|
Volume:
|
75,901 |
Market Cap:
|
50(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 2:45:35 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 1.85 One year: 2.14 |
| Support: |
Support1: 1.17 Support2: 0.97 |
| Resistance: |
Resistance1: 1.58 Resistance2: 1.84 |
| Pivot: |
1.35  |
| Moving Average: |
MA(5): 1.25 MA(20): 1.4
MA(100): 1.31  MA(250): 1.32 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 7.3 %D(3): 12.2 |
| RSI: |
RSI(14): 29.8 |
| 52-week: |
High: 2.41 Low: 0.83 |
| Average Vol(K): |
3-Month: 424 (K) 10-Days: 144 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ALGS ] has closed above bottom band by 9.8%. Bollinger Bands are 9.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.27 - 1.28 |
1.28 - 1.29 |
|
Low:
|
1.15 - 1.16 |
1.16 - 1.17 |
|
Close:
|
1.19 - 1.2 |
1.2 - 1.21 |
|
Company Description |
|
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California. |
Headline News |
Thu, 09 Mar 2023
Aligos Therapeutics, Inc. Misses Q4 EPS by 3c By Investing.com - Investing.com India
Thu, 09 Mar 2023
ALIGOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.com
Thu, 09 Mar 2023
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results - Yahoo Finance
Thu, 09 Mar 2023
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue ... - Nasdaq
Tue, 28 Feb 2023
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023 - Marketscreener.com
Thu, 16 Feb 2023
Aligos Therapeutics Presents Program Updates at the 32nd ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
40 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
16.4 (%) |
|
% Held by Institutions
|
66.5 (%) |
|
Shares Short
|
854 (K) |
|
Shares Short P.Month
|
730 (K) |
Stock Financials |
|
EPS
|
-2.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.42 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-701.7 |
|
Return on Assets (ttm)
|
-32 |
|
Return on Equity (ttm)
|
-66.6 |
|
Qtrly Rev. Growth
|
863.7 |
|
Gross Profit (p.s.)
|
-1.79 |
|
Sales Per Share
|
0.34 |
|
EBITDA (p.s.)
|
-2.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-79 (M) |
|
Levered Free Cash Flow
|
-44 (M) |
Stock Valuations |
|
PE Ratio
|
-0.56 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.49 |
|
Price to Sales
|
3.43 |
|
Price to Cash Flow
|
-0.61 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
